Skip to main content

Table 1 (abstract P197). See text for description

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

 

JIA (N=121)

p

MTXO: MTXSC, n

45 : 76

 

MTX dose, median (IQR) mg/m2/week

9.7 (9.0 – 10.9)

-

 MTXo : MTXSC

9.6 (9.0-10.7) : 9.8 (8.8-11.1)

0.86

MTX treatment duration, median (IQR) days

340 (142-766)

-

 MTXo : MTXSC

261 (143-543) : 417 (134-853)

0.39

BAI-Y raw score (total 0 – 60), mean (95%CI)

27.4 (26.2 – 28.6)

-

 MTXintol : MTXtol(MISS)

27.8 (26.1-29.4) :26.9 (25.3-28.6)

0.48

 MTX-induced nausea: All others (Diary)

28.0 (26.3-29.6) : 24.4 (22.8-26.0)

0.0024

Unfavourable Coping Strategies[1], mean (95% CI)

16.5 (15.5-17.5)

-

 MTXintol : MTXtol (MISS)

17.3 (15.9-18.7) :15.2 (13.8-16.5)

0.0287

 MTX-induced nausea: All others (Diary)

17.7 (16.2-19.3) :13.0 (11.6-14.4)

<0.0001